How Will DEA’s New Rules Impact Telemedicine Controlled Prescriptions?

January 21, 2025

The Drug Enforcement Administration (DEA) has unveiled a series of proposed updates aimed at reshaping the landscape of controlled substance prescriptions via telemedicine. Issued as a notice of proposed rulemaking (NPRM) on January 15, 2025, these regulations seek to introduce a more stringent framework to control the prescribing and dispensing of Schedules II-V substances. These changes come in anticipation of the expiration of COVID-19 telemedicine prescribing flexibilities on December 31, 2025. The proposed rules portend considerable impact on telemedicine companies, their operations, and their investors.

Limitations on Prescriptions

One of the central tenets of the DEA’s NPRM is the imposition of strict limitations on the ability of direct-to-consumer (DTC) telemedicine companies to prescribe Schedules II-V controlled substances. The rules mandate that prescriptions for medications such as Adderall and Ritalin, commonly used for attention deficit disorders, require an in-person consultation. This regulation directly responds to the over-prescription concerns that surfaced during the COVID-19 pandemic. The intention here is to curb potential misuse and ensure a thorough assessment of patient needs before powerful medications are prescribed.

Moreover, the new rules delineate that only specialized practitioners, like psychiatrists and hospice care physicians, will have the authority to prescribe Schedule II controlled substances. This initiative aims to ensure that these potent drugs are only prescribed by professionals who have the requisite expertise and training. The goal is to prevent misuse and ensure that these medications are dispensed responsibly, thereby safeguarding public health while maintaining the efficacy of telemedicine practices.

Burdensome Registration Requirements

Telemedicine platforms will encounter new, potentially onerous registration requirements under the proposed rules. To operate legally and prescribe controlled substances, these platforms will have to register with the DEA as “platform practitioners” and illustrate a “legitimate need” for approval. This registration process demands extensive documentation, including maintaining photographic records of patient IDs and ensuring the presence of parents for minors prescribed Schedule II substances. While these measures aim to enhance verification and safeguard the prescription process, they add significant administrative and operational burdens.

The complexity and time-consuming nature of the registration process present a palpable hurdle for clinicians and telemedicine platforms alike. Platforms must build a compelling case for their services to demonstrate the “legitimate need” for approval. For companies without a clear, definitive justification, these requirements might restrict their operational capacity, limiting their ability to serve patients efficiently. The added layer of bureaucracy is focused on ensuring that only platforms committed to high standards of care and patient safety can thrive in the telemedicine industry.

Geographical Limitations and Prescription Quotas

The proposed rules also establish stringent geographical limitations on the prescribing of Schedule II substances, requiring that clinicians and patients be located within the same state. This change presents a logistical challenge for telemedicine companies that operate across multiple states, necessitating a thorough understanding and compliance with varying local regulations and standards of care. The underlying purpose is to ensure clinicians’ adherence to state-specific guidelines, thereby enhancing the quality and appropriateness of care.

In addition to geographical constraints, the NPRM sets forth prescription quotas, stipulating that Schedule II medications should comprise less than 50% of a clinician’s total prescriptions in both telemedicine and traditional practice settings. This cap is meant to prevent the over-prescription of these powerful drugs, ensuring they are administered only when absolutely necessary. These measures reflect a commitment to balanced prescribing practices while posing operational and strategic adjustments for telemedicine providers striving to comply with the new regulations.

State Telemedicine Registration

A critical component of the new rules is the requirement for special registrants to obtain State Telemedicine Registrations in every state where they treat patients. Managed by the DEA, this process involves fees for both clinician and platform registrations, translating into substantial administrative demands for telemedicine companies. For platforms operating across numerous states, the necessity to secure multiple state-specific registrations adds a layer of complexity and cost, influencing their expansion strategies.

The intent behind this requirement is to equate telemedicine practitioners with traditional practitioners, ensuring adherence to state-specific regulations and fostering consistency in patient care standards. While it enhances regulatory compliance and patient safety, the demand for multiple registrations could impede the growth and scalability of telemedicine services, particularly for those companies aspiring to serve a nationwide patient base. The balancing act lies in strengthening regulatory oversight without stifling innovation and accessibility in telemedicine.

Electronic Prescribing and PDMP Checks

The DEA’s proposed updates mandate that all telemedicine prescriptions be completed electronically, accompanied by a national Prescription Drug Monitoring Program (PDMP) check. Although the full implementation of this requirement comes with a three-year delay, its implications are far-reaching. By mandating electronic prescribing and PDMP checks, the DEA aims to bolster the security and oversight of telemedicine practices, reducing the risk of drug misuse and diversion.

For telemedicine companies, these requirements necessitate significant investments in technology and infrastructure to comply with electronic prescribing standards and integrate PDMP checks into their operational workflows. While demanding, these technological upgrades promise to enhance the security, transparency, and accountability of telemedicine prescriptions. The focus is on safeguarding public health while modernizing and standardizing the prescription process across telemedicine platforms.

Telemedicine Encounter Requirements

The proposed rules specify that all telemedicine engagements, including initial consultations and follow-up visits, must utilize both audio and video communication. This stipulation is designed to ensure that clinicians conduct thorough assessments, closely monitor patient progress, and provide high-quality care. It represents a move toward more comprehensive and interactive telemedicine practices, enhancing the depth and effectiveness of virtual patient interactions.

While this requirement elevates the standard of care, it poses challenges for telemedicine companies that have relied heavily on audio-only consultations. Companies must adapt to the dual communication mode, necessitating upgrades in their technical capabilities and patient engagement strategies. Nevertheless, the emphasis on visual and auditory communication strengthens the clinician-patient relationship, ensuring that telemedicine continues to deliver effective and personalized medical care.

Minors and Schedule II Substances

Addressing the unique needs and vulnerabilities of minors, the proposed rules introduce specific provisions for prescribing Schedule II substances to pediatric patients. One of the key measures is the requirement for parents or guardians to be present during the prescription process, ensuring an added layer of safeguarding. This step is intended to protect minors from the potential risks and misuse of these powerful medications, echoing the broader commitment to responsible and prudent prescribing practices.

For telemedicine companies serving a large number of pediatric patients, this requirement presents logistical challenges. Ensuring parental presence may complicate the scheduling and execution of telemedicine consultations. However, this provision enhances the oversight and safety of prescribing practices for minors, aligning with the overarching goal of protecting vulnerable patient populations while facilitating access to necessary medical care through telemedicine.

Addressing Concerns of Over-Prescription and Misuse

The Drug Enforcement Administration (DEA) has introduced a proposal to update regulations concerning the prescription of controlled substances through telemedicine. This proposal, detailed in a notice of proposed rulemaking (NPRM) issued on January 15, 2025, aims to bring about significant changes in how Schedules II-V substances are prescribed and dispensed. The proposal seeks to establish a stricter regulatory framework, which stands to impact telemedicine providers, their operational procedures, and their investors. These upcoming changes are set against the backdrop of the COVID-19 pandemic, during which telemedicine saw a dramatic increase in use owing to temporary prescribing flexibilities. These flexibilities, however, are slated to expire on December 31, 2025. As such, the DEA’s proposed updates are anticipated to reshape the telemedicine landscape, introducing more rigorous measures to control the prescription processes of controlled substances. Telemedicine companies will therefore need to adapt to the new regulations, which are likely to influence their operational strategies and investment plans significantly. This move by the DEA signals a shift toward tighter oversight in telehealth, ensuring that controlled substances are prescribed responsibly while balancing the need for accessible healthcare services.

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later